Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies

Ophthalmology

Volumn 122, Issue 10, 2015, Pages 2044-2052

  Brown, David M ^a   Schmidt Erfurth, Ursula ^b   Do, Diana V ^c   Holz, Frank G ^d   Boyer, David S ^e   Midena, Edoardo ^f   Heier, Jeffrey S ^g   Terasaki, Hiroko ^h   Kaiser, Peter K ⁱ   Marcus, Dennis M ^j   Nguyen, Quan D ^c   Jaffe, Glenn J ^k   Slakter, Jason S ^l   Simader, Christian ^b   Soo, Yuhwen ^m   Schmelter, Thomas ⁿ   Yancopoulos, George D ^m   Stahl, Neil ^m   Vitti, Robert ^m   Berliner, Alyson J ^m   Zeitz, Oliver ^n,o   Metzig, Carola ⁿ   Korobelnik, Jean François ^p,q,r   more..

^a RETINA CONSULTANTS OF HOUSTON   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d UNIVERSITY OF BONN   (Germany)

^e RETINA VITREOUS ASSOCIATES MEDICAL GROUP   (United States)

^f UNIVERSITY OF PADOVA   (Italy)

^g TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h NAGOYA UNIVERSITY HOSPITAL   (Japan)

ⁱ LERNER RESEARCH INSTITUTE   (United States)

^j Southeast Retina Center   (United States)

^k DUKE UNIVERSITY EYE CENTER   (United States)

^l VITREOUS RETINA MACULA CONSULTANTS OF NEW YORK   (United States)

^m REGENERON PHARMACEUTICALS INC   (United States)

ⁿ BAYER PHARMA AG   (Germany)

^o UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^p HÔPITAL PELLEGRIN   (France)

^q UNIVERSITÉ DE BORDEAUX   (France)

^r INSERM   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

ARTICLE; BEST CORRECTED VISUAL ACUITY; CATARACT EXTRACTION; CONTROLLED STUDY; CORNEA DISEASE; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DIABETIC RETINOPATHY SEVERITY SCALE SCORE; DRUG EFFICACY; DRUG SAFETY; EYE DISEASE ASSESSMENT; HUMAN; HYPHEMA; INJECTION SITE INJURY; INJURY; INTRAOCULAR PRESSURE ABNORMALITY; LASER COAGULATION; LENS LUXATION; MACULAR DEGENERATION; MACULAR LASER PHOTOCOAGULATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PUNCTATE KERATITIS; RANDOMIZED CONTROLLED TRIAL; READING; RETINA ARTERY OCCLUSION; RETINA DETACHMENT; RETINA EXUDATE; RETINA HEMORRHAGE; RETINA ISCHEMIA; RETINA NEOVASCULARIZATION; SIDE EFFECT; SUBCAPSULAR CATARACT; VISUAL ACUITY; VISUAL FIELD DEFECT; VITREOUS HEMORRHAGE; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DOUBLE BLIND PROCEDURE; FLUORESCENCE ANGIOGRAPHY; INSULIN DEPENDENT DIABETES MELLITUS; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; PHYSIOLOGY; SICKNESS IMPACT PROFILE;

ANGIOGENESIS INHIBITORS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DOUBLE-BLIND METHOD; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; LASER COAGULATION; MACULAR EDEMA; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; SICKNESS IMPACT PROFILE; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84943453717     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2015.06.017     Document Type: Article

References (31)

1. D.S. Boyer, J.J. Hopkins, J. Sorof, and J.S. Ehrlich Anti-vascular endothelial growth factor therapy for diabetic macular edema Ther Adv Endocrinol Metab 4 2013 151 169
2. International Diabetes Foundation. IDF Diabetes Atlas. Available at: http://www.idf.org/diabetesatlas. Accessed November 20, 2014.
3. R.R. Bourne, J.B. Jonas, S.R. Flaxman, and et al. Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe: 1990-2010 Br J Ophthalmol 98 2014 629 638
4. I. Kocur, and S. Resnikoff Visual impairment and blindness in Europe and their prevention Br J Ophthalmol 86 2002 716 722
5. T.A. Ciulla, A.G. Amador, and B. Zinman Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies Diabetes Care 26 2003 2653 2664
6. R.J. Antcliff, and J. Marshall The pathogenesis of edema in diabetic maculopathy Semin Ophthalmol 14 1999 223 232
7. J.W. Yau, S.L. Rogers, R. Kawasaki, and et al. Global prevalence and major risk factors of diabetic retinopathy Diabetes Care 35 2012 556 564
8. Photocoagulation for diabetic macular edema Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group Arch Ophthalmol 103 1985 1796 1806
9. T.A. Ciulla, A. Harris, N. McIntyre, and C. Jonescu-Cuypers Treatment of diabetic macular edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide, dexamethasone implant, and fluocinolone acetonide implant Expert Opin Pharmacother 15 2014 953 959
10. L.P. Aiello Angiogenic pathways in diabetic retinopathy N Engl J Med 353 2005 839 841
11. R. Simo, J.M. Sundstrom, and D.A. Antonetti Ocular Anti-VEGF therapy for diabetic retinopathy: the role of VEGF in the pathogenesis of diabetic retinopathy Diabetes Care 37 2014 893 899
12. Q.D. Nguyen, D.M. Brown, D.M. Marcus, and et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE Ophthalmology 119 2012 789 801
13. M.J. Elman, H. Qin, L.P. Aiello, and et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results Ophthalmology 119 2012 2312 2318
14. U. Schmidt-Erfurth, G.E. Lang, F.G. Holz, and et al. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study Ophthalmology 121 2014 1045 1053
15. A.B. Nepomuceno, E. Takaki, F.P. Paes de Almeida, and et al. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema Am J Ophthalmol 156 2013 502 510 e2
16. R. Rajendram, S. Fraser-Bell, A. Kaines, and et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3 Arch Ophthalmol 130 2012 972 979
17. J.F. Korobelnik, D.V. Do, U. Schmidt-Erfurth, and et al. Intravitreal aflibercept for diabetic macular edema Ophthalmology 121 2014 2247 2254
18. M.J. Elman, L.P. Aiello, R.W. Beck, and et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema Ophthalmology 117 2010 1064 1077 e35
19. J. Holash, S. Davis, N. Papadopoulos, and et al. VEGF-Trap: a VEGF blocker with potent antitumor effects Proc Natl Acad Sci U S A 99 2002 11393 11398
20. N. Papadopoulos, J. Martin, Q. Ruan, and et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab Angiogenesis 15 2012 171 185
21. J.M. Rakic, V. Lambert, L. Devy, and et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization Invest Ophthalmol Vis Sci 44 2003 3186 3193
22. D.V. Do, U. Schmidt-Erfurth, V.H. Gonzalez, and et al. The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema Ophthalmology 118 2011 1819 1826
23. D.V. Do, Q.D. Nguyen, D. Boyer, and et al. One-year outcomes of the DA Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema Ophthalmology 119 2012 1658 1665
24. ICH Harmonized Tripartite Guideline. Guideline for Good Clinical Practice; 1996. Available at: http://www.ich.org/products/guidelines/efficacy/article/efficacy-guidelines.html. Accessed September 17, 2014.
25. U.S. Government Printing Office. Health Insurance Portability and Accountability Act of 1996. Available at: http://www.gpo.gov/fdsys/pkg/PLAW-104publ191/html/PLAW-104publ191.htm. Accessed September 17, 2014.
26. Fundus photographic risk factors for progression of diabetic retinopathy ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group Ophthalmology 98 1991 823 833
27. P. Mitchell, F. Bandello, U. Schmidt-Erfurth, and et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema Ophthalmology 118 2011 615 625
28. M. Michaelides, A. Kaines, R.D. Hamilton, and et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2 Ophthalmology 117 2010 1078 1086 e2
29. J.A. Wells, A.R. Glassman, A.R. Ayala, and et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema N Engl J Med 372 2015 1193 1203
30. M.J. Elman, N.M. Bressler, H. Qin, and et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema Ophthalmology 118 2011 609 614
31. H. Shikari, P.S. Silva, and J.K. Sun Complications of intravitreal injections in patients with diabetes Semin Ophthalmol 29 2014 276 289